Avapritinib
Sign in to save this workspacePrimary targets: PDGFRA, PDGFRB · FDA status: FDA Approved
Selectivity scorecard
KISS
97.73
Gini
0.644
CATDS
0.016
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Avapritinib. Strongest target: PDGFRA at 99.1% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDGFRA | 99.1% | 0.9% |
| 2 | C_KIT | 98.8% | 1.2% |
| 3 | LIMK1 | 98.4% | 1.6% |
| 4 | DDR1 | 96.0% | 4.0% |
| 5 | FMS | 95.9% | 4.1% |
| 6 | LCK | 92.7% | 7.3% |
| 7 | LYN | 91.4% | 8.6% |
| 8 | RET | 90.4% | 9.6% |
| 9 | PDGFRB | 90.4% | 9.6% |
| 10 | NEK5 | 89.7% | 10.3% |
| 11 | FLT3 | 88.6% | 11.4% |
| 12 | LIMK2 | 85.0% | 15.0% |
| 13 | FGR | 80.0% | 20.0% |
| 14 | BLK | 79.3% | 20.7% |
| 15 | YES_YES1 | 78.7% | 21.3% |
| 16 | NEK1 | 78.7% | 21.3% |
| 17 | FLT4_VEGFR3 | 76.0% | 24.0% |
| 18 | ABL1 | 75.1% | 24.9% |
| 19 | ERBB2_HER2 | 75.1% | 24.9% |
| 20 | CLK1 | 72.4% | 27.6% |
Selectivity landscape
Where Avapritinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Avapritinib.
Annotations
Sign in to read and post annotations.
Loading…